Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 1
1983 3
1984 3
1985 5
1986 1
1987 2
1988 4
1989 4
1990 4
1991 10
1992 8
1993 10
1994 25
1995 16
1996 22
1997 17
1998 18
1999 15
2000 26
2001 28
2002 28
2003 38
2004 42
2005 63
2006 73
2007 78
2008 91
2009 115
2010 134
2011 184
2012 187
2013 257
2014 348
2015 375
2016 370
2017 370
2018 457
2019 488
2020 618
2021 696
2022 806
2023 760
2024 397

Text availability

Article attribute

Article type

Publication date

Search Results

6,446 results

Results by year

Filters applied: . Clear all
Page 1
WGX50 mitigates doxorubicin-induced cardiotoxicity through inhibition of mitochondrial ROS and ferroptosis.
Tai P, Chen X, Jia G, Chen G, Gong L, Cheng Y, Li Z, Wang H, Chen A, Zhang G, Zhu Y, Xiao M, Wang Z, Liu Y, Shan D, He D, Li M, Zhan T, Khan A, Li X, Zeng X, Li C, Ouyang D, Ai K, Chen X, Liu D, Liu Z, Wei D, Cao K. Tai P, et al. Among authors: he d. J Transl Med. 2023 Nov 17;21(1):823. doi: 10.1186/s12967-023-04715-1. J Transl Med. 2023. PMID: 37978379 Free PMC article.
Research progress on phosphatidylinositol 4-kinase inhibitors.
Li G, Wu Y, Zhang Y, Wang H, Li M, He D, Guan W, Yao H. Li G, et al. Among authors: he d. Biochem Pharmacol. 2024 Feb;220:115993. doi: 10.1016/j.bcp.2023.115993. Epub 2023 Dec 25. Biochem Pharmacol. 2024. PMID: 38151075 Review.
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.
Yan XQ, Ye MJ, Zou Q, Chen P, He ZS, Wu B, He DL, He CH, Xue XY, Ji ZG, Chen H, Zhang S, Liu YP, Zhang XD, Fu C, Xu DF, Qiu MX, Lv JJ, Huang J, Ren XB, Cheng Y, Qin WJ, Zhang X, Zhou FJ, Ma LL, Guo JM, Ding DG, Wei SZ, He Y, Guo HQ, Shi BK, Liu L, Liu F, Hu ZQ, Jin XM, Yang L, Zhu SX, Liu JH, Huang YH, Xu T, Liu B, Sun T, Wang ZJ, Jiang HW, Yu DX, Zhou AP, Jiang J, Luan GD, Jin CL, Xu J, Hu JX, Huang YR, Guo J, Zhai W, Sheng XN. Yan XQ, et al. Among authors: he dl. Ann Oncol. 2024 Feb;35(2):190-199. doi: 10.1016/j.annonc.2023.09.3108. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37872020 Free article. Clinical Trial.
6,446 results